Financial statements are reported in EUR and shown here converted to USD at today's exchange rate.
GRFS — Grifols, S.A.
$8.69
$-0.11 (-1.25%)
Grifols, S.A., together with its subsidiaries, engages in the research, development, production, and marketing of plasma-derived medicines in the United States, Canada, Spain, Europe, and internationally. It operates through four segments: Biopharma, Diagnostic, Bio Supplies, and Others.
Market Cap
$5.91B
Forward P/E
7.0x
52-Week Range
N/A
GRFS Price History
Revenue vs. Net Income
$8.3B
Revenue · FY2025
Annual. Net margin is shown under each year.
Free Cash Flow
$688M
FCF · FY2025
Annual. FCF margin is shown under each year.
Return on Capital Employed (ROCE)
6.7%
ROCE · FY2025
Annual. Green above 0%, red below. Dashed line marks the 15% compounder threshold.
Total Assets vs. Total Liabilities
1.4x
Assets ÷ liabilities · FY2025
Annual. What the company owns against what it owes. Assets ÷ liabilities is shown under each year.
CapEx as % of Revenue
5.6%
CapEx · FY2025
Annual. Green at or under the 5% maximum target, red above it.
Shares Outstanding
+0.2%
Dilution · FY2025
Annual diluted shares. Under each year: the change on the previous year (green = buyback, amber = dilution).
